GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Oncoclinicas do Brasil Servicos Medicos ONCO3.SA · BRL

Health Care · B3 · 🇧🇷 Brazil

Compare

1.04

+6.12%

Close of 9 Nov 2026, in BRL

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in BRL, from our data supplier.

FY2025

Revenue

BRL 5.74bn

FY2016FY2025

Net income

−BRL 3.62bn

FY2016FY2025

Free cash flow

−BRL 271.3m

FY2016FY2025

Shareholders' equity

BRL 900.9m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueBRL 5.74bnBRL 6.23bnBRL 5.49bnBRL 4.09bnBRL 2.70bnBRL 2.04bnBRL 1.69bnBRL 1.05bnBRL 791.8mBRL 594.8m
Gross profitBRL 1.79bnBRL 2.06bnBRL 1.93bnBRL 1.45bnBRL 868.8mBRL 635.7mBRL 460.5mBRL 309.4mBRL 311.6mBRL 235.7m
Research and development——BRL 37,000————BRL 249,000BRL 547,000—
Operating income−BRL 2.39bn−BRL 166.3mBRL 758.0mBRL 470.6mBRL 180.5mBRL 32.1mBRL 122.0mBRL 82.7mBRL 68.2mBRL 40.0m
Net income−BRL 3.62bn−BRL 646.2mBRL 223.6mBRL 46.3m−BRL 46.9m−BRL 157.7m−BRL 20.4m−BRL 17.1mBRL 3.1m−BRL 25.4m
Diluted earnings per share-5.38-1.020.410.07-0.11-0.39-0.05-0.050.01-0.11

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsBRL 7.13bnBRL 11.20bnBRL 9.18bnBRL 8.22bnBRL 6.03bnBRL 3.39bnBRL 2.11bnBRL 1.35bnBRL 786.4mBRL 619.1m
Cash and short-term investmentsBRL 510.3mBRL 1.89bnBRL 761.4mBRL 1.09bnBRL 2.01bnBRL 787.1mBRL 447.3mBRL 198.9mBRL 89.2mBRL 69.8m
Total liabilitiesBRL 6.07bnBRL 7.82bnBRL 6.50bnBRL 5.59bnBRL 3.73bnBRL 2.71bnBRL 1.45bnBRL 878.2mBRL 554.0mBRL 374.5m
DebtBRL 3.33bnBRL 5.48bnBRL 4.56bnBRL 3.47bnBRL 2.43bnBRL 1.63bnBRL 835.4mBRL 397.4mBRL 126.4mBRL 49.9m
Shareholders' equityBRL 900.9mBRL 3.15bnBRL 2.30bnBRL 2.12bnBRL 1.85bnBRL 401.8mBRL 556.7mBRL 383.1mBRL 181.0mBRL 194.3m
Shares outstanding674m633m546m690m415m402m400m359m292m225m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−BRL 103.2m−BRL 184.9m−BRL 51.6m−BRL 271.6m−BRL 9.3mBRL 97.6mBRL 97.1mBRL 38.9mBRL 135.3m−BRL 20.7m
Capital spending−BRL 168.1m−BRL 214.2m−BRL 311.7m−BRL 304.2m−BRL 201.9m−BRL 204.8m−BRL 190.2m−BRL 238.5m−BRL 34.6m−BRL 26.6m
Free cash flow−BRL 271.3m−BRL 399.1m−BRL 363.3m−BRL 575.8m−BRL 211.2m−BRL 107.2m−BRL 93.1m−BRL 199.6mBRL 100.6m−BRL 47.3m
Dividends paid−BRL 36.8m−BRL 11.7m−BRL 59.7m−BRL 18.3m−BRL 26.4m−BRL 45.2m−BRL 22.8m−BRL 18.4m−BRL 19.2m—

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueBRL 1.05bnBRL 1.16bnBRL 1.37bnBRL 1.41bnBRL 1.46bnBRL 1.49bnBRL 1.57bnBRL 1.63bn
Gross profitBRL 229.3mBRL 347.8mBRL 480.9mBRL 453.1mBRL 440.0mBRL 412.2mBRL 503.1mBRL 548.1m
Operating income−BRL 86.0m−BRL 113.6m−BRL 885.1m−BRL 1.66bnBRL 50.0mBRL 31.1m−BRL 703.1mBRL 205.5m
Net income−BRL 469.0m−BRL 364.2m−BRL 1.45bn−BRL 1.88bn−BRL 141.0m−BRL 146.5m−BRL 643.1m−BRL 15.9m
Diluted earnings per share-0.72-0.56-2.16-2.79-0.21-0.22-1.02-0.03
Cash from operationsBRL 122.0m−BRL 214.0mBRL 271.0mBRL 151.0m−BRL 449.0m−BRL 76.0mBRL 32.0mBRL 112.0m
Capital spending−BRL 15.0m−BRL 26.0m−BRL 36.0m−BRL 52.0m−BRL 38.0m−BRL 39.0m−BRL 32.0m−BRL 53.0m
Free cash flowBRL 107.0m−BRL 240.0mBRL 235.0mBRL 99.0m−BRL 487.0m−BRL 115.0mBRL 0BRL 59.0m
Total assetsBRL 6.60bnBRL 6.70bnBRL 7.13bnBRL 8.22bnBRL 10.30bnBRL 10.83bnBRL 11.20bnBRL 12.27bn
Cash and short-term investmentsBRL 145.3mBRL 112.3mBRL 510.3mBRL 473.2mBRL 968.0mBRL 1.64bnBRL 1.89bnBRL 2.16bn
DebtBRL 3.44bnBRL 3.38bnBRL 3.33bnBRL 4.86bnBRL 5.31bnBRL 5.46bnBRL 5.48bnBRL 5.79bn
Shareholders' equityBRL 16.5mBRL 533.4mBRL 900.9mBRL 971.2mBRL 2.85bnBRL 3.00bnBRL 3.15bnBRL 3.79bn

Financial ratios

Data as of 22 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2018FY2017
Gross margin31.1%33.1%35.1%35.5%32.2%31.2%——
Operating margin-44.0%-0.9%15.7%12.7%8.0%2.0%——
Net margin-63.1%-10.4%4.1%1.1%-1.7%-7.7%——
Return on equity-402.2%-20.5%9.7%2.2%-2.5%-39.2%——
Return on assets-50.8%-5.8%2.4%0.6%-0.8%-4.6%——
Free cash flow yield9.2%4.4%45.4%4.5%44.2%71.7%——
Revenue growth-7.8%13.5%34.3%51.3%32.8%20.5%——
Earnings growth460.8%-389.0%383.4%-198.6%-70.3%672.3%——
Current ratio0.56x1.90x1.71x1.50x2.41x1.40x——
Debt to equity3.70x1.58x1.83x1.50x1.18x3.56x——
Equity ratio12.6%28.1%25.1%25.8%30.7%11.8%——
Interest coverage-3.97x-0.09x1.54x1.20x1.40x0.44x——
R&D as a share of sales——0.0%———0.0%0.1%
Buybacks as a share of market value-6.5%-16.0%20.9%-66.3%-3.2%———

Growth per year

Compound annual rate

3 years5 years10 years
Revenue12.0%23.0%28.8%
Net income—87.2%64.6%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin32.1%33.5%33.2%33.2%
Operating margin-21.3%-6.1%-4.2%-2.5%
Net margin-35.7%-18.6%-16.0%-13.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-0.5-2.331.789.9-99.5
Price to sales0.30.21.31.01.7

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.